Related Experiment Video

Updated: May 5, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.7K

INDIVIDUAL ARTICLE: NECOM 5: Algorithm for the Treatment and Supportive Management of Targeted Therapy-Related

Ada Girnita, Peter Bjerring, Gabriela Lladó Grove

    Journal of Drugs in Dermatology : JDD
    |March 5, 2025
    PubMed
    Abstract

    Insights

    Targeted therapy can cause skin issues. A new algorithm helps prevent and manage these side effects, improving cancer patient quality of life.

    Area of Science:

    • Oncodermatology
    • Cancer Therapeutics
    • Clinical Dermatology

    Background:

    • Substantial cancer burden in Nordic countries necessitates improved patient care.
    • Targeted therapies enhance survival but can cause cutaneous adverse events (cAEs).
    • Lack of practical clinical tools for managing cAEs in cancer patients and survivors.

    Framework:

    • The Nordic European Cutaneous Oncodermatology Management (NECOM) project aims to address cAEs.
    • NECOM 5 focuses on developing a practical algorithm for targeted therapy-related cAEs (TTcAEs).
    • Previous NECOM studies covered general cAEs, radiation therapy, and immunotherapy-related cAEs.

    Implementation:

    • A consensus-based practical algorithm for TTcAEs was developed by the NECOM panel.
    • The algorithm incorporates systematic review findings, expert opinion, and Nordic clinical settings.
    • It includes general skin care and prevention, plus specific management for common TTcAEs like rash and hand-foot syndrome.

    Implications:

    • TTcAEs significantly impact cancer patient and survivor quality of life.
    • The NECOM algorithm provides a valuable clinical tool for managing TTcAEs.
    • Implementation of this algorithm can improve cancer patient outcomes and quality of life.

    More Related Videos

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    21.3K
    A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis07:22

    A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

    Published on: March 14, 2025

    200

    Related Concept Videos

    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    8.5K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.0K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K
    Skin Cancer01:30

    Skin Cancer

    Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
    Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
    5.2K
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.5K
    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
    820